Pharmaceuticals

NOVARTIS AG

Salesforce

Conference Minutes

OpenAI

DXYZ

INFA

GOOG

GOOGL

GGLS

GGLL

ARR-C

<p>The following are the minutes of the FY26Q3 earnings call for <span class="security-tag" type="security-tag" counter_id="ST/US/CRM" name="Salesforce" trend="">$Salesforce(CRM.US)</span> compiled by Dolphin Research. For an interpretation of the earnings report, please refer to the article &#34;Salesforce: Is the AI Agent 'Delayed', and Has the SaaS Leader Become a Value Stock?&#34; 1. Review of Core Financial Information Guidance: The company is still expected to reaccelerate revenue growth within the next 12 to 18 months. Net new AOV growth: Net new AOV growth in the second half of FY26 is expected to exceed AOV growth in the second half...</p>

Destiny Tech100

Haleon

IRSA Inversiones

Informatica

Alphabet - C

Alphabet

Direxion Daily Googl Bear 1x Shares

Direxion Daily GOOGL Bull 2X Shares

Armour Residential Reit

Hasbro

ING Groep

Gartner

ARMOUR RESIDENTIAL REIT INC 7.00% CUM RED PFD STK SER C

Salesforce (Minutes): The foundation of technology and sales has been laid, looking forward to the harvest period

Novartis' ianalumab significantly extends disease control time for patients with immune thrombocytopenia

Novartis Reports Kisqali® Effectiveness in Breast Cancer Patients

Novartis and Relation Therapeutics Reach $1.7 Billion Drug Target Deal

JPMorgan Raises Novartis' Rating and Price Target

Legal & General Group Plc Increased Its Stake in Novartis AG

Morgan Stanley Raises Novartis Target Price to 115 Swiss Francs

Fisher Asset Management LLC Increased Holdings in Novartis

Level Four Advisory Services LLC Increased Stake in Novartis

Elevation Point Wealth Partners LLC reduces stake in Novartis AG

The number of initial jobless claims in the U.S. hits a new low for the week ending November 22

Novartis' Rimepelimtasib Approved for Chronic Spontaneous Urticaria

US Bank Upgrades Novartis Stock Rating and Target Price

Novartis Stan Site May Cut Up to 550 Jobs

Novartis to Present Data from Over 70 Abstracts at ASH Annual Meeting and SABCS

Novartis Announces Positive Phase III Clinical Trial Results for ITP Patients with i­analumab

Novartis Announces ITVISMA Pricing and Patient Payment Plan

Novartis Receives FDA Approval for ITVISMA® to Treat Spinal Muscular Atrophy

Bernstein Analyst Maintains Buy Rating on Novartis

US Bank Securities Reaffirms Neutral Rating on Novartis

Novartis Raises Sales Guidance for Kisqali and Scemblix

Aimei Health Tech

Oriental Culture

Netcapital

Lion

JX Luxventure

ALPHAVEST ACQUISITION CORP ORD USD0.0001(S/R 22/01/26)

Designer Brands

Horizon Space Acquisition I

Cypherpunk Tech

Alexander & Baldwin

Pinned News

置顶新闻

Key facts: Novartis reports strong Kisqali® results; $1.7B deal with Relation

Novartis (NVS.US) 2024 Third Quarter Earnings Conference Call

禮來

ROCHE HOLDINGS AG

羅氏(ADR)

阿斯利康

諾華制藥

諾和諾德公司

中外制藥(ADR)

UCB(ADR)

第一三共株式會社(ADR)

大塚制藥(ADR)

Style Score

Growth Score

Revenue YoY

Net Profit YoY

Value Score

P/B Ratio

Dividend Ratio

Size Score

Market Cap Score

Market Cap

Revenue Score

Revenue

Multi Score

Profit Score

Profit Margin

Gross Margin

Total Assets YoY

Net Assets YoY

Cash Score

Cash Flow Margin

OCF YoY

Operating Score

Turnover

Debt Score

Gearing Ratio